Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EX-042
- Development stage
- Preclinical
- Lead developer
- Excelsior
- Modality
- Small Molecules
01
Overview
EX-042 is a small-molecule modulator of the Transforming Growth Factor-beta (TGF-β) signaling pathway, currently in preclinical development by Excelsior Group. The drug is being investigated for two primary therapeutic applications: the promotion of wound healing and the treatment of pulmonary arterial hypertension (PAH). By targeting TGF-β, EX-042 aims to regulate tissue repair processes and address the pathological vascular remodeling associated with PAH. It is a lead candidate within Excelsior's TGF-β Research Center, which focuses on developing inhibitors with novel mechanisms of action to treat rare diseases, fibrosis, and inflammation.
Beyond the preview
Go deeper on EX-042.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EX-042.